Press Releases

04.09.2020

Pfizer Advances Battle Against COVID-19 on Multiple Fronts

04.08.2020

U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy

04.07.2020

Pfizer to Hold Virtual-Only 2020 Annual Meeting of Shareholders

04.06.2020

Pfizer and The Pfizer Foundation Donate $40 Million in Charitable Grants, Expand Product Access and Mobilize Colleagues to Combat COVID-19 Pandemic

04.02.2020

Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab)

04.02.2020

Susan Desmond-Hellmann Elected to Pfizer’s Board of Directors

04.01.2020

Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic

03.27.2020

Pfizer Completes $1.25 Billion Sustainability Bond for Social and Environmental Impact

03.26.2020

Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn

03.24.2020

U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of EUCRISA® (Crisaborole) Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis

03.18.2020

Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older

03.18.2020

 Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch